非小細胞肺がん市場- 世界の産業規模、動向、機会、予測、種類別、治療別、薬剤クラス別、エンドユーザー別、地域別、競合別、2020～2030年

非小細胞肺がんの世界市場は2024年に198億1,000万米ドルと評価され、予測期間には361億3,000万米ドルに達すると予測され、2030年までのCAGRは10.51%です。

世界の非小細胞肺がん（NSCLC）市場は、治療オプションの進歩や疾患の根本的メカニズムの理解向上により、大きな成長を遂げています。肺がんの中で最も一般的なNSCLCは、診断精度が向上し、早期発見と予後の改善が可能になりました。標的治療や免疫療法など、個別化治療レジメンの採用が進むにつれ、NSCLC管理の状況は劇的に変化しています。リキッドバイオプシーや分子プロファイリングを含む高度な診断技術の出現により、がんの進行に関連する遺伝子変異やマーカーが同定され、より正確な治療目標が設定できるようになりました。このため、EGFR阻害剤やALK阻害剤のような、特定の遺伝子変異に合わせた治療法の需要が高まっています。さらに、従来の化学療法に免疫療法や標的薬を組み合わせた併用療法は、患者の転帰を著しく改善することが示されています。

世界のヘルスケア支出の増加とがん研究に対する政府資金の増加が、市場の成長にさらに貢献しています。免疫チェックポイント阻害薬などの新しい薬剤クラスのイントロダクションは、NSCLC患者の治療アプローチに革命をもたらしました。ペムブロリズマブやニボルマブのような薬剤は生存率の向上に有望であり、これらの治療薬に対する需要の高まりにつながっています。進行中の臨床試験と治療アプローチにおけるブレークスルーが、引き続き市場の技術革新を促進しています。さらに、コンパニオン診断薬の進歩により、医療従事者はより効果的に治療を個別化できるようになり、新しい治療法の成功に貢献しています。その結果、製薬企業やバイオテクノロジー企業は、より効果的な治療法に対する需要の高まりに対応するため、NSCLCの医薬品開発に多額の投資を行っています。

同市場には大きな成長の可能性がある一方で、特に治療費の手頃さや先進的治療へのアクセスの面で課題が残っています。特に標的治療薬や免疫療法などの新規がん治療薬は高額であるため、特に中低所得国では患者アクセスが制限されることが多いです。さらに、NSCLCの治療レジメンは複雑なため副作用が生じやすく、患者の長期治療へのアドヒアランスが懸念されます。医薬品承認に関わる規制上のハードルや、より包括的な臨床データの必要性も、新しい治療薬が市場に出回るスピードを妨げています。このような課題にもかかわらず、特にNSCLCに関する調査によって新たなバイオマーカーや治療アプローチが発見され続けていることから、成長の機会は豊富にあります。早期発見、患者中心の治療、侵襲性の低い治療法の開発への注目の高まりは、製薬企業やバイオテクノロジー企業にとって今後数年間の大きなチャンスとなります。

主な市場促進要因

診断技術の進歩

人口動態とライフスタイルの変化

主な市場課題

治療に対する耐性

主要市場動向

精密医療と標的治療

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の非小細胞肺がん市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 種類別（腺がん、扁平上皮がん、大細胞がん）
  • 治療別（化学療法、免疫療法、放射線療法、手術、標的治療薬）
  • 薬剤クラス別（血管新生阻害剤、上皮成長因子受容体阻害剤、キナーゼ阻害剤、微小管安定剤、葉酸代謝拮抗剤、PD-1/PD-L1阻害剤）
  • エンドユーザー別（病院・クリニック、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 北米の非小細胞肺がん市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の非小細胞肺がん市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域の非小細胞肺がん市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米の非小細胞肺がん市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの非小細胞肺がん市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界の非小細胞肺がん市場：SWOT分析

第14章 競合情勢

• Bayar Healthcare AG
• Eli Lilly & Co.
• Biogen Inc
• Merck$Co
• AbbVie Inc
• AstraZeneca PLC
• Novartis AG
• Pfizer Inc
• Avid Bioservices Inc
• Blueprint Medicines Company

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Non-Small Cell Lung Cancer Market was valued at USD 19.81 Billion in 2024 and is expected to reach USD 36.13 Billion in the forecast period with a CAGR of 10.51% through 2030. The global Non-Small Cell Lung Cancer (NSCLC) market is experiencing significant growth due to advancements in treatment options and a better understanding of the disease's underlying mechanisms. NSCLC, the most common form of lung cancer, has seen a rise in diagnostic accuracy, allowing for earlier detection and improved prognosis. With the increasing adoption of personalized treatment regimens, such as targeted therapies and immunotherapies, the landscape for NSCLC management has dramatically shifted. The emergence of advanced diagnostic technologies, including liquid biopsy and molecular profiling, has helped identify genetic mutations and markers associated with cancer progression, allowing for more accurate treatment targeting. This has fueled demand for therapies tailored to specific genetic mutations, such as EGFR and ALK inhibitors. Furthermore, combination therapies, which pair traditional chemotherapy with immunotherapies or targeted drugs, have shown to significantly improve patient outcomes.

Rising healthcare expenditure globally and increased government funding for cancer research have further contributed to the market's growth. The introduction of new drug classes, such as immune checkpoint inhibitors, has revolutionized the treatment approach for NSCLC patients. Drugs like pembrolizumab and nivolumab have shown promise in increasing survival rates, leading to heightened demand for these therapies. Ongoing clinical trials and breakthroughs in treatment approaches continue to drive innovation in the market. Furthermore, advancements in companion diagnostics have enabled healthcare providers to personalize treatments more effectively, contributing to the success of new therapies. As a result, pharmaceutical companies and biotechnology firms are investing heavily in NSCLC drug development to meet the growing demand for more effective treatments.

While the market presents substantial growth potential, challenges persist, particularly in terms of treatment affordability and access to advanced therapies. The high cost of novel cancer treatments, especially targeted therapies and immunotherapies, often limits patient access, particularly in low- and middle-income countries. Moreover, the complexity of NSCLC treatment regimens can result in adverse side effects, leading to concerns about patient adherence to long-term therapies. The regulatory hurdles involved in drug approval and the need for more comprehensive clinical data are also impeding the speed at which new therapies reach the market. Despite these challenges, opportunities for growth are abundant, especially as research into NSCLC continues to uncover new biomarkers and treatment approaches. The increasing focus on early-stage detection, patient-centric care, and the development of less invasive therapies presents significant opportunities for pharmaceutical and biotechnology companies in the coming years.

Key Market Drivers

Advances in Diagnostic Technologies

Advances in diagnostic technologies are playing a crucial role in driving the growth of the global Non-Small Cell Lung Cancer (NSCLC) market. Early and accurate detection of NSCLC significantly impacts treatment outcomes and survival rates. Traditional diagnostic methods, such as X-rays and CT scans, are now complemented by more advanced technologies, including high-resolution imaging, molecular profiling, and next-generation sequencing (NGS). These innovations allow for more precise tumor characterization, enabling physicians to identify specific genetic mutations and alterations in NSCLC tumors, such as EGFR, ALK, and ROS1 mutations, which can be targeted by specific therapies. According to the American Cancer Society, lung cancer is the leading cause of cancer-related deaths in the United States, with an estimated 228,820 new cases and 135,720 deaths projected for 2020.

Liquid biopsy techniques have emerged as a significant breakthrough in NSCLC diagnostics. Liquid biopsies are non-invasive, requiring only blood samples to detect cancer-related biomarkers, including circulating tumor DNA (ctDNA) and exosomes. This method enables real-time monitoring of tumor progression, detection of resistance mutations, and evaluation of treatment efficacy. Liquid biopsy's ability to provide continuous, non-invasive updates on a patient's condition reduces the need for invasive tissue biopsies and provides valuable insights into the molecular dynamics of the tumor. A study published in the Journal of Clinical Oncology reported that integrating liquid biopsy into the clinical practice of patients with NSCLC increased actionable aberration detection rates by 42% when tissue NGS was not performed.

Immunohistochemistry (IHC) and molecular imaging techniques, such as positron emission tomography (PET), are improving the detection of early-stage tumors and providing accurate assessments of the tumor's location and size. These advanced diagnostic tools are helping to stratify patients based on their disease stage and molecular profile, facilitating the selection of personalized treatment regimens, including targeted therapies and immunotherapies. The National Lung Screening Trial (NLST) demonstrated that low-dose CT screening could reduce lung cancer mortality by 20% compared to chest X-ray, highlighting the importance of early detection.

As diagnostic technologies continue to evolve, they contribute to more effective treatment decision-making, better patient outcomes, and improved survival rates, making them a key driver in the growth of the NSCLC market.

Shifting Demographics and Lifestyle Choices

The global population is aging, with a significant rise in the elderly demographic. As NSCLC is more prevalent among older individuals, this demographic shift has led to a higher incidence of the disease. Advances in healthcare have led to increased life expectancy. However, with age, the risk of NSCLC also rises. This demographic trend is driving the demand for both diagnostic and treatment services. While the prevalence of smoking has declined in some regions, it remains a major risk factor for NSCLC. The persistence of smoking habits among certain demographic groups continues to contribute to NSCLC incidence. Environmental factors, such as exposure to second-hand smoke and occupational hazards like asbestos, play a role in NSCLC development. Demographic groups with higher exposure to these factors face an increased risk.

Genetic predisposition to NSCLC can significantly influence its occurrence. Certain demographic groups may have a higher prevalence of genetic mutations that increase susceptibility to the disease. NSCLC risk can vary among different ethnicities due to genetic differences. Understanding these demographic variations is crucial for tailored prevention and treatment strategies.

Demographic disparities in healthcare access, often related to socio-economic factors, can impact early diagnosis and timely treatment initiation. Awareness of NSCLC risk factors and early symptoms can vary among different demographic groups. This influences the stage at which patients seek medical attention. Targeted interventions to promote smoking cessation, especially among high-risk demographic groups, can contribute to a reduction in NSCLC cases. Promoting healthy lifestyle choices, such as regular exercise and a balanced diet, can reduce NSCLC risk and improve overall health within specific demographics.

Key Market Challenges

Resistance to Treatment

Challenge: One of the foremost challenges in the NSCLC market is the development of resistance to treatment. NSCLC is known for its ability to adapt and evolve, often rendering initially effective therapies ineffective over time. This resistance can occur in response to chemotherapy, targeted therapies, and immunotherapies.

NSCLC tumors exhibit a high degree of heterogeneity, meaning that different regions of the tumor may have distinct genetic profiles. This heterogeneity can result in the survival of resistant cell populations. Genetic mutations within tumors can lead to the development of resistance mechanisms. For example, mutations in the EGFR gene can lead to resistance to EGFR inhibitors. The tumor microenvironment can foster drug resistance by creating conditions that protect cancer cells from treatment-induced damage.Identifying which patients will develop resistance and when it will occur remains a significant challenge. This hampers the ability to proactively manage resistance.

Resistance to treatment not only limits the effectiveness of existing therapies but also necessitates the development of new drugs and treatment strategies. This can increase the cost and complexity of NSCLC care and hinder overall market growth.

Key Market Trends

Precision Medicine and Targeted Therapies

Precision medicine and targeted therapies have emerged as pivotal trends in the treatment of Non-Small Cell Lung Cancer (NSCLC), revolutionizing the way this disease is managed. Advances in genomic profiling have enabled the identification of specific mutations, such as EGFR, ALK, ROS1, and BRAF, which are responsible for the growth and progression of NSCLC. By targeting these mutations directly, therapies can achieve higher efficacy and fewer side effects compared to conventional chemotherapy. These treatments are tailored to the genetic makeup of an individual's tumor, allowing for more personalized and effective care. The use of targeted therapies such as tyrosine kinase inhibitors (TKIs) has demonstrated improved progression-free survival rates and overall survival in patients with specific mutations.

The increasing use of next-generation sequencing (NGS) technologies is playing a crucial role in precision medicine by facilitating the detection of a wide range of genetic alterations in NSCLC. This technology enables healthcare providers to identify actionable biomarkers that guide treatment decisions, helping to optimize patient outcomes. For instance, the development of therapies like osimertinib for EGFR-mutant NSCLC and crizotinib for ALK-positive NSCLC has significantly advanced the treatment landscape, offering patients more effective and less toxic alternatives to traditional treatments.

The trend towards precision medicine is further fueled by the growing understanding of the tumor microenvironment and its role in tumor progression and resistance mechanisms. Researchers are now focused on identifying biomarkers that can predict not only response to therapies but also the potential for resistance, enabling more proactive and adaptive treatment strategies. As these targeted therapies continue to evolve, they are expected to dominate the NSCLC market, paving the way for more precise, personalized treatment regimens tailored to the unique genetic characteristics of each patient's cancer.

Segmental Insights

Type Insights

Based on the Type, Adenocarcinoma emerged as the dominant segment in the Global Non-Small Cell Lung Cancer Market in 2024. Non-Small Cell Lung Cancer, adenocarcinoma has emerged as the dominant player. Factors such as changing smoking patterns, environmental influences, advances in diagnostics, and the availability of targeted therapies have all contributed to its prominence within the global NSCLC market. As research continues to advance and our understanding of adenocarcinoma deepens, we can expect even more tailored and effective treatments for this prevalent subtype of lung cancer. Advancements in diagnostic techniques, particularly the widespread adoption of computed tomography (CT) scans and the development of molecular testing, have facilitated the early detection of adenocarcinoma. This early detection allows for more timely intervention and potentially better treatment outcomes. One of the most significant factors contributing to adenocarcinoma's dominance is the availability of targeted therapies. Adenocarcinoma is often associated with specific genetic mutations, such as EGFR and ALK. Targeted therapies that directly address these mutations have shown remarkable efficacy in treating adenocarcinoma patients, further solidifying its position in the NSCLC market. These factors are expected to drive the growth of this segment.

Key Market Players

• Bayar Healthcare AG
• Eli Lilly & Co.
• Biogen Inc
• Merck & Co
• AbbVie Inc
• AstraZeneca PLC
• Novartis AG
• Pfizer Inc
• Avid Bioservices Inc
• Blueprint Medicines Company

Report Scope:

In this report, the Global Non-Small Cell Lung Cancer Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-Small Cell Lung Cancer Market, By Type:

• Adenocarcinoma
• Squamous Cell Carcinoma
• Large Cell Carcinoma

Non-Small Cell Lung Cancer Market, By Treatment:

• Chemotherapy
• Immunotherapy
• Radiation Therapy
• Surgery
• Targeted Therapy Drugs

Non-Small Cell Lung Cancer Market, By Drug Class:

• Angiogenesis Inhibitor
• Epidermal Growth Factor Receptor Blocker
• Kinase Inhibitor
• Microtubule Stabilizer
• Folate Antimetabolites
• PD-1/ PD-L1 Inhibitor

Non-Small Cell Lung Cancer Market, By End-User:

• Hospitals & Clinics
• Others

Non-Small Cell Lung Cancer Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Non-Small Cell Lung Cancer Market.

Available Customizations:

Global Non-Small Cell Lung Cancer market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Drug Class
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Non-Small Cell Lung Cancer Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Adenocarcinoma, Squamous Cell Carcinoma, Large Cell Carcinoma)
  • 5.2.2. By Treatment (Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, Targeted Therapy Drugs)
  • 5.2.3. By Drug Class (Angiogenesis Inhibitor, Epidermal Growth Factor Receptor Blocker, Kinase Inhibitor, Microtubule Stabilizer, Folate Antimetabolites, PD-1/ PD-L1 Inhibitor)
  • 5.2.4. By End-User (Hospitals & Clinics, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Non-Small Cell Lung Cancer Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Treatment
  • 6.2.3. By Drug Class
  • 6.2.4. By End-User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Non-Small Cell Lung Cancer Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By Drug Class
      • 6.3.1.2.4. By End-User
  • 6.3.2. Canada Non-Small Cell Lung Cancer Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By Drug Class
      • 6.3.2.2.4. By End-User
  • 6.3.3. Mexico Non-Small Cell Lung Cancer Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By Drug Class
      • 6.3.3.2.4. By End-User

7. Europe Non-Small Cell Lung Cancer Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Treatment
  • 7.2.3. By Drug Class
  • 7.2.4. By End-User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Non-Small Cell Lung Cancer Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By Drug Class
      • 7.3.1.2.4. By End-User
  • 7.3.2. United Kingdom Non-Small Cell Lung Cancer Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By Drug Class
      • 7.3.2.2.4. By End-User
  • 7.3.3. Italy Non-Small Cell Lung Cancer Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By Drug Class
      • 7.3.3.2.4. By End-User
  • 7.3.4. France Non-Small Cell Lung Cancer Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Treatment
      • 7.3.4.2.3. By Drug Class
      • 7.3.4.2.4. By End-User
  • 7.3.5. Spain Non-Small Cell Lung Cancer Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Treatment
      • 7.3.5.2.3. By Drug Class
      • 7.3.5.2.4. By End-User

8. Asia-Pacific Non-Small Cell Lung Cancer Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Treatment
  • 8.2.3. By Drug Class
  • 8.2.4. By End-User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Non-Small Cell Lung Cancer Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By Drug Class
      • 8.3.1.2.4. By End-User
  • 8.3.2. India Non-Small Cell Lung Cancer Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By Drug Class
      • 8.3.2.2.4. By End-User
  • 8.3.3. Japan Non-Small Cell Lung Cancer Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By Drug Class
      • 8.3.3.2.4. By End-User
  • 8.3.4. South Korea Non-Small Cell Lung Cancer Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Treatment
      • 8.3.4.2.3. By Drug Class
      • 8.3.4.2.4. By End-User
  • 8.3.5. Australia Non-Small Cell Lung Cancer Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Treatment
      • 8.3.5.2.3. By Drug Class
      • 8.3.5.2.4. By End-User

9. South America Non-Small Cell Lung Cancer Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Treatment
  • 9.2.3. By Drug Class
  • 9.2.4. By End-User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Non-Small Cell Lung Cancer Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By Drug Class
      • 9.3.1.2.4. By End-User
  • 9.3.2. Argentina Non-Small Cell Lung Cancer Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By Drug Class
      • 9.3.2.2.4. By End-User
  • 9.3.3. Colombia Non-Small Cell Lung Cancer Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By Drug Class
      • 9.3.3.2.4. By End-User

10. Middle East and Africa Non-Small Cell Lung Cancer Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Treatment
  • 10.2.3. By Drug Class
  • 10.2.4. By End-User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Non-Small Cell Lung Cancer Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Treatment
      • 10.3.1.2.3. By Drug Class
      • 10.3.1.2.4. By End-User
  • 10.3.2. Saudi Arabia Non-Small Cell Lung Cancer Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Treatment
      • 10.3.2.2.3. By Drug Class
      • 10.3.2.2.4. By End-User
  • 10.3.3. UAE Non-Small Cell Lung Cancer Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Treatment
      • 10.3.3.2.3. By Drug Class
      • 10.3.3.2.4. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Non-Small Cell Lung Cancer Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Bayar Healthcare AG
• 14.2. Eli Lilly & Co.
• 14.3. Biogen Inc
• 14.4. Merck $ Co
• 14.5. AbbVie Inc
• 14.6. AstraZeneca PLC
• 14.7. Novartis AG
• 14.8. Pfizer Inc
• 14.9. Avid Bioservices Inc
• 14.10.Blueprint Medicines Company

15. Strategic Recommendations

16. About Us & Disclaimer